ELOC (elongin C)

2016-12-01  

Identity

HGNC
LOCATION
8q21.11
LOCUSID
ALIAS
SIII,TCEB1

Other Information

Locus ID:

NCBI: 6921
MIM: 600788
HGNC: 11617
Ensembl: ENSG00000154582

Variants:

dbSNP: 6921
ClinVar: 6921
TCGA: ENSG00000154582
COSMIC: ELOC

RNA/Proteins

Gene IDTranscript IDUniprot
ENSG00000154582ENST00000284811Q15369
ENSG00000154582ENST00000284811A0A024R7Y5
ENSG00000154582ENST00000518127Q15369
ENSG00000154582ENST00000518127A0A024R7Y5
ENSG00000154582ENST00000519082E5RHG8
ENSG00000154582ENST00000519487Q15369
ENSG00000154582ENST00000519487A0A024R7Y5
ENSG00000154582ENST00000520210Q15369
ENSG00000154582ENST00000520242Q15369
ENSG00000154582ENST00000520242A0A024R7Y5
ENSG00000154582ENST00000522337Q15369
ENSG00000154582ENST00000522337A0A024R7Y5
ENSG00000154582ENST00000523815Q15369
ENSG00000154582ENST00000523815A0A024R7Y5
ENSG00000154582ENST00000602840R4GMY8
ENSG00000154582ENST00000622804Q15369
ENSG00000154582ENST00000622804A0A024R7Y5

Expression (GTEx)

0
5
10
15
20
25
30
35
40

Pathways

PathwaySourceExternal ID
Ubiquitin mediated proteolysisKEGGko04120
Renal cell carcinomaKEGGko05211
Ubiquitin mediated proteolysisKEGGhsa04120
Pathways in cancerKEGGhsa05200
Renal cell carcinomaKEGGhsa05211
ECV complexKEGGhsa_M00383
ECS complexKEGGhsa_M00388
ECS complexKEGGM00388
HIF-1 signaling pathwayKEGGhsa04066
ECV complexKEGGM00383
DiseaseREACTOMER-HSA-1643685
Infectious diseaseREACTOMER-HSA-5663205
HIV InfectionREACTOMER-HSA-162906
HIV Life CycleREACTOMER-HSA-162587
Late Phase of HIV Life CycleREACTOMER-HSA-162599
Transcription of the HIV genomeREACTOMER-HSA-167172
HIV Transcription ElongationREACTOMER-HSA-167169
Tat-mediated elongation of the HIV-1 transcriptREACTOMER-HSA-167246
Formation of HIV-1 elongation complex containing HIV-1 TatREACTOMER-HSA-167200
HIV elongation arrest and recoveryREACTOMER-HSA-167287
Formation of HIV elongation complex in the absence of HIV TatREACTOMER-HSA-167152
Pausing and recovery of HIV elongationREACTOMER-HSA-167290
Tat-mediated HIV elongation arrest and recoveryREACTOMER-HSA-167243
Pausing and recovery of Tat-mediated HIV elongationREACTOMER-HSA-167238
Host Interactions of HIV factorsREACTOMER-HSA-162909
Vif-mediated degradation of APOBEC3GREACTOMER-HSA-180585
Immune SystemREACTOMER-HSA-168256
Adaptive Immune SystemREACTOMER-HSA-1280218
Class I MHC mediated antigen processing & presentationREACTOMER-HSA-983169
Antigen processing: Ubiquitination & Proteasome degradationREACTOMER-HSA-983168
Gene ExpressionREACTOMER-HSA-74160
Generic Transcription PathwayREACTOMER-HSA-212436
Transcriptional Regulation by TP53REACTOMER-HSA-3700989
RNA Polymerase II TranscriptionREACTOMER-HSA-73857
RNA Polymerase II Pre-transcription EventsREACTOMER-HSA-674695
RNA Polymerase II Transcription ElongationREACTOMER-HSA-75955
Formation of RNA Pol II elongation complexREACTOMER-HSA-112382
Cellular responses to stressREACTOMER-HSA-2262752
Cellular response to hypoxiaREACTOMER-HSA-2262749
Regulation of Hypoxia-inducible Factor (HIF) by oxygenREACTOMER-HSA-1234174
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor AlphaREACTOMER-HSA-1234176
TP53 Regulates Transcription of DNA Repair GenesREACTOMER-HSA-6796648

References

Pubmed IDYearTitleCitations
380580352023[Clinicopathological and molecular genetic characteristics of ELOC mutated renal cell carcinoma].0
380580352023[Clinicopathological and molecular genetic characteristics of ELOC mutated renal cell carcinoma].0
318138092021Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course.11
341630322021NF-κB-activated SPRY4-IT1 promotes cancer cell metastasis by downregulating TCEB1 mRNA via Staufen1-mediated mRNA decay.12
318138092021Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course.11
341630322021NF-κB-activated SPRY4-IT1 promotes cancer cell metastasis by downregulating TCEB1 mRNA via Staufen1-mediated mRNA decay.12
318509092020"Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.17
319417752020Elongin C Contributes to RNA Polymerase II Degradation by the Interferon Antagonist NSs of La Crosse Orthobunyavirus.6
323036052020Novel genetic characterisation and phenotype correlation in von Hippel-Lindau (VHL) disease based on the Elongin C binding site: a large retrospective study.2
318509092020"Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.17
319417752020Elongin C Contributes to RNA Polymerase II Degradation by the Interferon Antagonist NSs of La Crosse Orthobunyavirus.6
323036052020Novel genetic characterisation and phenotype correlation in von Hippel-Lindau (VHL) disease based on the Elongin C binding site: a large retrospective study.2
301664532018CRL4(AMBRA1) targets Elongin C for ubiquitination and degradation to modulate CRL5 signaling.12
301664532018CRL4(AMBRA1) targets Elongin C for ubiquitination and degradation to modulate CRL5 signaling.12
256616532015Insights into Cullin-RING E3 ubiquitin ligase recruitment: structure of the VHL-EloBC-Cul2 complex.41

Citation

Dessen P

ELOC (elongin C)

Atlas Genet Cytogenet Oncol Haematol. 2016-12-01

Online version: http://atlasgeneticsoncology.org/gene/56669